DorothyJ.ParkMD
Oncology • Beverly Hills, CABreast Cancer, Hematologic Oncology
Assistant Professor, Medicine, UCLA School of Medicine
Dr. Park is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9090 Wilshire Blvd
Ste 200
Beverly Hills, CA 90211Phone+1 310-888-8680Fax+1 310-888-1886
Education & Training
Cedars-Sinai Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1987 - 1990
David Geffen School of Medicine at UCLAClass of 1987
Certifications & Licensure
CA State Medical License 1989 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Radiation Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Breast Cancer Study of Preoperative Pembrolizumab + Radiation Start of enrollment: 2017 Dec 22
Publications & Presentations
PubMed
- 2 citationsA phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer.David B Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez
NPJ Breast Cancer. 2023-06-21 - 3 citationsScleroderma in a Patient on Capecitabine: Is this a Variant of Hand-Foot Syndrome?Muhammad Wasif Saif, Archana Agarwal, James Hellinger, Dorothy J. Park, Elizabeth R. Volkmann
Cureus. 2016-06-30 - 26 citationsRTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiationSigal Gery, Dorothy J. Park, Peter T. Vuong, Renu K. Virk, Claudia I. Muller
Experimental Hematology. 2007-04-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
